Hemispherx Biopharma (NYSE: HEB) agreed to sell up to $16 million in common stock and warrants in a registered offering ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE